Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease.
The objective of our study was to investigate whether an interaction exists between apolipoprotein E (APOE) genotype and the response of patients with Alzheimer's disease (AD) to selegiline treatment, and whether APOE genotype independently affects the rate of AD progression. A 48-week multicenter double-blind trial was undertaken on 43 patients with mild to moderate AD. Primary efficacy measures were the AD Assessment Scale (ADAS), an 11-item cognitive subscale of ADAS (ADAS-Cog/11) and the Mini Mental State Examination. Secondary outcome measures were Clinical Global Impression of severity and CGI of change scales. The therapeutic response to selegiline was not affected by APOE genotype. Our results revealed that the APOE4 allele carrier AD probands did not respond better to selegiline treatment than the APOE2-3 patients, i.e. APOE status did not influence the therapeutic outcome of selegiline treatment.
Kálmán
János
J
Department of Psychiatry, Albert Szent-Györgyi Center for Medical and Pharmaceutical Sciences, Faculty of Medicine, University of Szeged, Semmelweis u.6, H-6725 Szeged, Hungary. kalmanj@nepsy.szote.u-szeged.hu
Juhász
Anna
A
Rimanóczy
Agnes
A
Palotás
András
A
Palotás
Miklós
M
Szabó
Zoltán
Z
Boda
Krisztina
K
Márki-Zay
János
J
Janka
Zoltán
Z
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics*; D053329:Apolipoprotein E2; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics*; D004311:Double-Blind Method; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D011446:Prospective Studies; D012642:Selegiline / Q000008:administration & dosage*; D016896:Treatment Outcome
D053329:Apolipoprotein E2; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D018696:Neuroprotective Agents; D012642:Selegiline